NBIX vs. RGEN, EXEL, HALO, DNLI, ADPT, BIIB, TECH, QGEN, PCVX, and ARGX
Should you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), and argenx (ARGX). These companies are all part of the "biological products, except diagnostic" industry.
Neurocrine Biosciences (NASDAQ:NBIX) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Neurocrine Biosciences currently has a consensus price target of $148.96, suggesting a potential upside of 4.69%. Repligen has a consensus price target of $197.75, suggesting a potential upside of 15.01%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Neurocrine Biosciences.
Neurocrine Biosciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 1.2% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Neurocrine Biosciences has higher revenue and earnings than Repligen. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences received 582 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 77.58% of users gave Neurocrine Biosciences an outperform vote while only 68.08% of users gave Repligen an outperform vote.
Neurocrine Biosciences has a net margin of 18.65% compared to Repligen's net margin of 2.44%. Neurocrine Biosciences' return on equity of 17.45% beat Repligen's return on equity.
In the previous week, Neurocrine Biosciences had 16 more articles in the media than Repligen. MarketBeat recorded 19 mentions for Neurocrine Biosciences and 3 mentions for Repligen. Repligen's average media sentiment score of 1.05 beat Neurocrine Biosciences' score of 0.80 indicating that Repligen is being referred to more favorably in the news media.
Summary
Neurocrine Biosciences beats Repligen on 12 of the 19 factors compared between the two stocks.
Get Neurocrine Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurocrine Biosciences Competitors List
Related Companies and Tools
